EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Loss of IGF ‐ 1R impairs DNA ‐ PKcs recruitment to chromatin leading to defective end‐joining

Matthew O Ellis iD, Jack V Mills, Wojciech Niedzwiedz iD, Valentine M Macaulay

Molecular Oncology · 2026-11 · 20 (11) · 2876-2895

DOI: 10.1002/1878-0261.70266 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 07.05.2026. Verfasst von Matthew O Ellis und 3 weiteren Autor:innen. Beteiligte Einrichtung: UK-DRI, Department of Clinical Neuroscience, University of Cambridge, Cambridge, England. Hauptthemen laut MEDLINE: DNA End-Joining Repair, Receptor, IGF Type 1, DNA-Activated Protein Kinase, Chromatin. Die Arbeit nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK, Medical Research Council, Prostate Cancer UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The insulin‐like growth factor (IGF) axis regulates cancer cell proliferation, growth, invasion, and therapy resistance. Elevated expression of the type 1 IGF receptor (IGF‐1R) is linked to radioresistance and biochemical recurrence in prostate cancer, yet the molecular mechanisms underlying IGF‐1R–mediated DNA damage responses remain unclear. We investigated the role of IGF‐1R in DNA double‐strand break (DSB) repair by assessing chromatin recruitment of DNA repair proteins, repair pathway usage, and therapeutic sensitivity in cancer cell models with altered IGF‐1R status. Loss of IGF‐1R impaired DNA‐dependent protein kinase catalytic subunit (DNA‐PKcs) localisation to chromatin, resulting in defective non‐homologous end‐joining (NHEJ) and a compensatory reliance on alternative repair pathways, including microhomology‐mediated end‐joining (MMEJ). Modulating IGF‐1R expression restored radiosensitivity in poly (ADP‐ribose) polymerase (PARP) inhibitor–resistant breast cancer cells. IGF‐1R inhibition compromises canonical DSB repair and re‐sensitises resistant cancer cells to therapy, supporting its potential as a therapeutic strategy in homologous recombination–deficient tumours. Furthermore, IGF‐1R mutant cancers may benefit from targeted inhibition of the MMEJ pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA End-Joining RepairReceptor, IGF Type 1DNA-Activated Protein KinaseChromatinHumansCell Line, TumorDNA Breaks, Double-StrandedRadiation Tolerance

Stichwörter der Autor:innen

DNA repairIGF‐1RIrradiationprostate cancer

Substanzen

Receptor, IGF Type 1DNA-Activated Protein KinaseChromatin

Autor:innen und Institutionen

  • UK-DRI, Department of Clinical Neuroscience, University of Cambridge, Cambridge, England.
  • Nuffield Department of Surgical Sciences, University of Oxford, Oxford, England.
  • Institute of Cancer Research, London, England.

ORCID-Profile: Matthew O Ellis, Wojciech Niedzwiedz

Förderung

  • Cancer Research UK
  • Medical Research Council
  • Prostate Cancer UK

Zitieren

APA

Ellis, M. O., Mills, J. V., Niedzwiedz, W., & Macaulay, V. M. (2026). Loss of IGF ‐ 1R impairs DNA ‐ PKcs recruitment to chromatin leading to defective end‐joining. Molecular Oncology, 20(11), 2876-2895. https://doi.org/10.1002/1878-0261.70266

Vancouver

Ellis MO, Mills JV, Niedzwiedz W, Macaulay VM. Loss of IGF ‐ 1R impairs DNA ‐ PKcs recruitment to chromatin leading to defective end‐joining. Molecular Oncology. 2026;20(11):2876-2895. doi:10.1002/1878-0261.70266

BibTeX
@article{Ellis2026,
  author = {Ellis, Matthew O and Mills, Jack V and Niedzwiedz, Wojciech and Macaulay, Valentine M},
  title = {Loss of IGF ‐ 1R impairs DNA ‐ PKcs recruitment to chromatin leading to defective end‐joining},
  journal = {Molecular Oncology},
  year = {2026},
  volume = {20},
  number = {11},
  pages = {2876--2895},
  doi = {10.1002/1878-0261.70266}
}
Kostenlos starten →